Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME)

M. Imbimbo, M. Ottaviano, M. Vitali, A. Fabbri, G. Leuzzi, M. Fiore, D. Franceschini, G. Pasello, M. Perrino, M. Schiavon, G. Pruneri, A.P. Dei Tos, C. Sangalli, M.C. Garassino, R. Berardi, A. Alessi, G. Calareso, I. Petrini, M. Scorsetti, V. ScottiL. Rosso, F. Rea, U. Pastorino, P.G. Casali, S. Ramella, U. Ricardi, L. Abate-Daga, V. Torri, A. Trama, G. Palmieri, M. Marino, P.A. Zucali, TYME network collaborators

Research output: Contribution to journalArticle

Abstract

Thymic epithelial tumors (TETs) are a heterogenous group of rare tumors, with a complex histopatological classification. Furthermore, the recent introduction of the first TNM staging system, that is scheduled to replace the Masaoka-Koga system, may create further difficulties in TET management, that remains challenging. Several guidelines for treatment of TETs are available and provide recommendations based mainly on non randomized trials and retrospective or limited series. Often the lack of evidence leads to formulation of indications based on expert opinions. As for other rare cancers it is crucial to create networks to coordinate the work among centres involved in treatment of these diseases in order to offer the best diagnostic and therapeutic tools. For this purpose, in 2014 a network named TYME (ThYmic MalignanciEs), was founded in Italy with the aim of improving care and research in TETs. In September 2017 a panel of multidisciplinary experts from TYME network and from other Italian centres strongly involved in TET diagnosis and treatment convened a first Italian Expert meeting together with representatives of association for patients affected by rare thoracic cancers Tu.To.R, to explore how these tumors are managed in the different centres of Italy compared to ESMO guidelines. In this paper we summarize the issues discussed during that meeting and we propose recommandations based on Masaoka Koga and the new TNM staging system. © 2018 Elsevier Ltd
Original languageEnglish
Pages (from-to)76-87
Number of pages12
JournalCancer Treatment Reviews
Volume71
DOIs
Publication statusPublished - Dec 2018

Keywords

  • avelumab
  • capecitabine
  • carboplatin
  • cisplatin
  • cyclophosphamide
  • doxorubicin
  • etoposide
  • fluorouracil
  • gemcitabine
  • ifosfamide
  • imatinib
  • nivolumab
  • octreotide
  • paclitaxel
  • pembrolizumab
  • pemetrexed
  • prednisone
  • ramucirumab
  • sunitinib
  • contrast medium, cancer radiotherapy
  • cancer staging
  • clinical practice
  • epithelium tumor
  • health care
  • health center
  • human
  • Italy
  • medical expert
  • minimally invasive surgery
  • multidisciplinary team
  • phase 2 clinical trial (topic)
  • practice guideline
  • Review
  • thymoma
  • total quality management
  • adjuvant chemotherapy
  • autoimmune disease
  • diagnostic imaging
  • female
  • male
  • neoplasm
  • pathology
  • procedures
  • tumor recurrence
  • x-ray computed tomography, Autoimmune Diseases
  • Chemotherapy, Adjuvant
  • Contrast Media
  • Female
  • Humans
  • Male
  • Neoplasm Recurrence, Local
  • Neoplasms, Glandular and Epithelial
  • Thymus Neoplasms
  • Tomography, X-Ray Computed

Fingerprint Dive into the research topics of 'Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME)'. Together they form a unique fingerprint.

  • Cite this